Substance / Medication

Tretinoin

Overview

Active Ingredient
tretinoin
RxNorm CUI
10753

Indications

(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) fine RENOVA (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. RENOVA (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) offacial wrinkles in patients who use comprehensive skin care and sunlight avoidance

Labeler: Bausch Health US LLCUpdated: 2026-02-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components. It should be discontinued if hypersensitivity to any of its ingredients is noted.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

106 trials linked to this intervention

106
Total Trials
6
Recruiting
66
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Systematic Review of Rare Major Adverse Cardiovascular Events Associated With the Treatment of Acne With Isotretinoin.
Cowan Timothy L, Stark Madeleine, Sarmiento Simona et al. · Australas J Dermatol · 2025
PMID: 39927601Meta-AnalysisFull text (PMC)
Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review.
Siddiqui Zoya, Zufall Alina, Nash Marissa et al. · Am J Clin Dermatol · 2024
PMID: 39348007Meta-Analysis
Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris.
Kontzias Christina, Zaino Mallory, Feldman Steven R · Ann Pharmacother · 2023
PMID: 36639853Meta-Analysis
Use of topical tretinoin and the development of noncutaneous adverse events: evidence from a systematic review of the literature.
Shapiro Stanley, Heremans Annie, Mays David A et al. · J Am Acad Dermatol · 2011
PMID: 21550137Meta-Analysis
Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis.
Nighland Marge, Grossman Rachel · J Drugs Dermatol · 2008
PMID: 18724648Meta-Analysis
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris.
Schlessinger Joel, Menter Alan, Gold Michael et al. · J Drugs Dermatol · 2007
PMID: 17668526Meta-Analysis
Assessing the efficacy and safety profiles of 0.025% tretinoin in treating axillary hyperpigmentation with acanthosis nigricans: a randomized double-blinded study.
Chunekamrai Puri, Chatpimolkul Nattasit, Thummawatwimon Soravit et al. · Arch Dermatol Res · 2025
PMID: 39833642RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tretinoin (substance)
SNOMED CT
387305002
UMLS CUI
C0040845
RxNorm CUI
10753
Labeler
Bausch Health US LLC

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
106
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.